FDA expands Olumiant approval to adolescents with severe alopecia areata

The expanded indication extends Lilly's JAK inhibitor to adolescents aged 12 years and older with severe alopecia areata.

The FDA has expanded the approval of Olumiant (baricitinib) to include patients aged 12 years and older with severe alopecia areata.

The decision was supported by the Phase III BRAVE-AA-PEDS study, extending a treatment previously available in the US for adults with severe alopecia areata to eligible adolescents.

Field	Content
Field	Content
Alert Type	FDA Indication Expansion
Company	Eli Lilly and Company
Product	Olumiant (baricitinib)
Indication	Severe alopecia areata
Patient Population	Patients aged 12 years and older
Technology/Modality	JAK inhibitor
Regulator	U.S. Food and Drug Administration
Regulatory Status	Expanded FDA approval
Clinical Study	Phase III BRAVE-AA-PEDS
What Happened	FDA expanded Olumiant's approval to include adolescents aged 12 years and older with severe alopecia areata.
Why It Matters	The decision extends an established systemic treatment for severe alopecia areata to a younger patient population.
Supporting Evidence	The approval was supported by the Phase III BRAVE-AA-PEDS study.
Previous Population	Olumiant was previously approved in the US for adults with severe alopecia areata.
Potential Impact	Eligible adolescents with severe alopecia areata gain access to an FDA-approved systemic treatment already used in adults.
Key Takeaway	Olumiant's US alopecia areata indication now covers patients from age 12.
What to Watch	Adolescent uptake, treatment guidelines and post-approval safety and effectiveness data.
Primary Source	Eli Lilly and Company
Relevant Date	25 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com